AU2016905362A0 - Compounds and use thereof in methods of treatment - Google Patents

Compounds and use thereof in methods of treatment

Info

Publication number
AU2016905362A0
AU2016905362A0 AU2016905362A AU2016905362A AU2016905362A0 AU 2016905362 A0 AU2016905362 A0 AU 2016905362A0 AU 2016905362 A AU2016905362 A AU 2016905362A AU 2016905362 A AU2016905362 A AU 2016905362A AU 2016905362 A0 AU2016905362 A0 AU 2016905362A0
Authority
AU
Australia
Prior art keywords
compounds
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016905362A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of AU2016905362A0 publication Critical patent/AU2016905362A0/en
Priority to KR1020197021576A priority Critical patent/KR102572077B1/en
Priority to CA3048040A priority patent/CA3048040A1/en
Priority to EP17884538.4A priority patent/EP3558293A4/en
Priority to CN201780086511.1A priority patent/CN110536685A/en
Priority to PCT/AU2017/051439 priority patent/WO2018112545A1/en
Priority to JP2019534124A priority patent/JP2020506884A/en
Priority to US16/472,882 priority patent/US11434190B2/en
Priority to AU2017383102A priority patent/AU2017383102B2/en
Priority to US17/741,065 priority patent/US20230100768A1/en
Priority to JP2022162614A priority patent/JP2023011613A/en
Priority to US18/342,312 priority patent/US20240002326A1/en
Abandoned legal-status Critical Current

Links

AU2016905362A 2016-12-23 2016-12-23 Compounds and use thereof in methods of treatment Abandoned AU2016905362A0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2017383102A AU2017383102B2 (en) 2016-12-23 2017-12-21 Inhibitors of SOX18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases
PCT/AU2017/051439 WO2018112545A1 (en) 2016-12-23 2017-12-21 Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases
CA3048040A CA3048040A1 (en) 2016-12-23 2017-12-21 Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases
EP17884538.4A EP3558293A4 (en) 2016-12-23 2017-12-21 Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases
CN201780086511.1A CN110536685A (en) 2016-12-23 2017-12-21 The inhibitor of SOX18 protein active is for treating angiogenesis-associated diseases and/or lymphatic vessel generation related disease
KR1020197021576A KR102572077B1 (en) 2016-12-23 2017-12-21 Inhibitors of SOX18 protein activity for the treatment of angiogenesis- and/or lymphangiogenesis-related disorders
JP2019534124A JP2020506884A (en) 2016-12-23 2017-12-21 Inhibitors of SOX18 protein activity for treatment of diseases associated with angiogenesis and / or lymphangiogenesis
US16/472,882 US11434190B2 (en) 2016-12-23 2017-12-21 Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseases
US17/741,065 US20230100768A1 (en) 2016-12-23 2022-05-10 Inhibitors of sox18 protein activity for treating angiogenesis and/or lymphangiogenesis-related diseases
JP2022162614A JP2023011613A (en) 2016-12-23 2022-10-07 Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases
US18/342,312 US20240002326A1 (en) 2016-12-23 2023-06-27 Compounds and use thereof in methods of treatment

Publications (1)

Publication Number Publication Date
AU2016905362A0 true AU2016905362A0 (en) 2017-01-12

Family

ID=

Similar Documents

Publication Publication Date Title
EP3429635A4 (en) Anti-crispr compounds and methods of use
EP3504213A4 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
EP3454945A4 (en) Ash1l inhibitors and methods of treatment therewith
EP3328419A4 (en) Pd-1-binding molecules and methods of use thereof
EP3377042A4 (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
EP3303634A4 (en) Cas9 variants and methods of use thereof
EP3302562A4 (en) Lag-3-binding molecules and methods of use thereof
EP3548033A4 (en) Compounds and their methods of use
EP3325473A4 (en) Compounds and uses thereof in the treatment of cancers and other medical conditions
EP3371306B8 (en) Materials and methods for treatment of hemoglobinopathies
EP3487379A4 (en) Medical devices and methods of use
EP3253387A4 (en) Compounds and uses in treatment of senescence-associated conditons
EP3377070A4 (en) Compounds and methods of their use
EP3554401A4 (en) Ocular treatment devices and related methods of use
EP3373969A4 (en) Glycan-interacting compounds and methods of use
EP3576738A4 (en) Use of gaboxadol in the treatment of tinnitus
EP3526205A4 (en) Therapeutic compounds and methods of use thereof
EP3133919A4 (en) Agents and methods for treatment of pathogens
EP3706736A4 (en) Ash1l degraders and methods of treatment therewith
EP3525703A4 (en) Treatment devices and methods
EP3541847A4 (en) Glycan-interacting compounds and methods of use
EP3496804A4 (en) Bioelectric devices and methods of use
EP3236992A4 (en) Peptides and their use in the treatment of skin
EP3134108A4 (en) Agents and methods of treatment
EP3145573A4 (en) Portable medical treatment system and method of use